Ertumaxomab
| Monoclonal antibody | |
|---|---|
| Type | Trifunctional antibody |
| Source | Rat/mouse hybrid |
| Target | HER2/neu, CD3 |
| Clinical data | |
| Trade names | Rexomun |
| ATC code |
|
| Identifiers | |
| CAS Number | |
| ChemSpider |
|
| UNII | |
  (what is this?) (verify) | |
Ertumaxomab (trade name Rexomun) is a rat-murine hybrid monoclonal antibody designed to treat some types of cancer.
It is a trifunctional antibody which works by linking T-lymphocytes and macrophages to the cancer cells.[1][2]
Phase II clinical trial evaluating the treatment of breast cancer was terminated due to change in Fresenius' development plans.[3] (So they could concentrate on their other product catumaxomab (trade name Removab).[4]: 35 )
References
- ^ "Capital Market Day Fresenius Biotech: Fresenius Concentrates Biotechnology Activities on Antibody and Innovative Cell Therapies". Fresenius. 15 January 2004. Archived from the original on 1 October 2011.
- ^ Kiewe P, Thiel E (October 2008). "Ertumaxomab: a trifunctional antibody for breast cancer treatment". Expert Opinion on Investigational Drugs. 17 (10): 1553–1558. doi:10.1517/13543784.17.10.1553. PMID 18808314.
- ^ Clinical trial number NCT00522457 for "Phase II Study With the Trifunctional Antibody Ertumaxomab to Treat Metastatic Breast Cancer After Progression on Trastuzumab Therapy " at ClinicalTrials.gov
- ^ "2009 Consolidated Financial Statements and Management Report of Fresenius SE" (PDF). Archived from the original (PDF) on 2016-03-31. Retrieved 2016-03-20.